Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Jan 19, 2021
Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.
Next Investors Dec 02, 2020
Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.
We put out a short note on Creso Pharma (ASX: CPH) to some of you that might have previously invested in the stock and not had a positive experience. After a couple of false starts, our plan is to ride this momentum over the coming weeks and hopefully recoup some of our previous losses.
Next Investors Archived Oct 13, 2020
While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.
Get expert stock analysis direct in your inbox
Next Investors Oct 13, 2020
Long term Creso Pharma (ASX: CPH) shareholders have had a rough ride in the last 12 months. Last week the $20M capped CPH raised circa A$9M at $0.0291 per share, finally extinguishing the company’s debt and ridding the company of major con note holders that were hampering any share price appreciation.
Next Investors Archived Jun 19, 2020
Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.
Next Investors Archived May 05, 2020
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
Next Investors Archived Mar 24, 2020
Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.
Next Investors Archived Mar 11, 2020
ASX Junior Creso Pharma (ASX: CPH) has appointed two former Canopy executives to the senior management team of its wholly-owned Mernova Medical Inc. in Nova Scotia, Canada.
Next Investors Archived Mar 04, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.
Next Investors Archived Mar 02, 2020
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
Next Investors Archived Feb 11, 2020
Creso Pharma (ASX:CPH) today announced the successful development of anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.
Next Investors Archived Feb 06, 2020
Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,
Next Investors Archived Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
Next Investors Archived Jan 28, 2020
Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.
Next Investors Archived Jan 21, 2020
Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.
Next Investors Archived Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Next Investors Archived Dec 09, 2019
Creso Pharma (ASX:CPH | FRA:1X8) has announced that through Pharma Dynamics, Creso’s partner in the African region, initial orders worth approximately A$300,000 for the cannaQIX® product range have been made.
Join Our Mailing List
